1 October 2012 - Qualyst Transporter Solutions LLC, a company that commercialises novel and proprietary drug transport and hepatobiliary disposition products for drug discovery and development, announced on Friday that it has introduced a contract research service that uses a clinically relevant model to assess a compound’s potential to modify the transport and metabolism of bilirubin.

Bilirubin contract research services can be conducted in hepatocytes from all major toxicology species, including humans.

Dr. Kenneth R. Brouwer, CSO for Qualyst Transporter Solutions, said, ’An integrated in vitro system, like sandwich-cultured hepatocytes, with multiple expressed, localised, and functioning, uptake and efflux transporters, and metabolic capacity is required to accurately predict and describe in vivo alterations in bilirubin disposition.’